en · de · es · fr · pt
analytical-notes.peptides6608.com › Topic › Background And Regulatory History — Worked Examples

Background And Regulatory History — Worked Examples

By Editorial Desk · published 2025-11-12 · last reviewed 2025-12-03 · Topic

Everything below concerns PPARδ agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-12-03. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Regulatory History

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Mechanism and Research Context

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Cardarine at a glance

PropertyValueNotes
Common nameCardarineCommon internet and media name.
Research codeGW501516Also written GW-1516.
Drug classPPARδ agonistNot a selective androgen receptor modulator.
Development statusDiscontinuedClinical development halted after rodent cancer findings.
Regulatory statusProhibited in sportListed by WADA; not approved as medicine.

Background and Research Context

In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

Related pages on this site

Detection, Regulation, and Quality Context

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Reference notes

== Chemistry == Retatrutide is a peptide with the following amino acid sequence YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³ where letters with superscripted numbers refer to the following chemical modifications:

Greater than 10%: difficulty sleeping, anxiety, nervousness, abdominal pain/cramps, nausea and/or vomiting, low energy, joint/muscle pain, and headache. Less than 10%: loss of appetite, diarrhea, constipation, thirstiness, increased energy, feeling down, irritability, dizziness, skin rash, delayed ejaculation, erectile dysfunction, and chills. A variety of other adverse events have also been reported with less than 1% incidence.

== History == The first documented example of an aerogel was created by Samuel Stephens Kistler in 1931, as a result of a bet with Charles Learned over who could replace the liquid in "jellies" with gas without causing shrinkage.

=== United Kingdom === Public Health England reported that the total number of antibiotic resistant infections in England rose by 9% from 55,812 in 2017 to 60,788 in 2018, but antibiotic consumption had fallen by 9% from 20.0 to 18.2 defined daily doses per 1,000 inhabitants per day between 2014 and 2018.

Sources: en.wikipedia.org

Reference notes

== Applications == NanoSIMS can capture the spatial variability of isotopic and elemental measurements of sub-micron areas, grains or inclusions from geological, materials science and biological samples. This instrument can characterise nanostructured materials with complex composition that are increasingly important candidates for energy generation and storage.

In 1929, Ruben Rausing and Erik Åkerlund established a food carton company in Malmö. Rausing, who had studied in New York at the beginning of the 1920s, had seen self-service grocery stores in the United States, unheard of in Europe at the time, and realised that pre-packaging was part of the future in food retailing as a more hygienic and practical way of distributing staple groceries. At the time, these were sold over the counter in cumbersome glass bottles or impractical paper wraps in most European countries. At the end of the 1920s, Rausing bought a run-down packaging factory in Malmö together with the industrialist Erik Åkerlund. Åkerlund & Rausing was the first packaging company in Scandinavia and eventually became a leading manufacturer of dry food cartons, producing various paper packaging for dry staple groceries.

=== Bio-based coloured materials === Cellulose nanocrystals have shown the possibility to self organize into chiral nematic structures with angle-dependent iridescent colours. It is thus possible to manufacture totally bio-based pigments and glitters, films including sequins having a metallic glare and a small footprint compared to fossil-based alternatives.

Other physiological factors include neurotransmitters and hormones that impact positive feelings, such as endorphin, dopamine, serotonin, oxytocin, and cortisol. Biologists are also interested in the evolutionary origins of subjective well-being. This perspective understands happiness and unhappiness not as ends but as tools to regulate behavior, guiding it toward fitness-enhancing outcomes. It holds that subjective well-being is a product of natural selection: its underlying hereditary traits are passed on to future generations if they promote survival and reproduction. In neuroscience, researchers try to uncover the neural correlates of well-being using neuroimaging techniques, such as functional magnetic resonance imaging. The problem of well-being plays a central role in medicine since medical interventions typically aim to restore, secure, and enhance patient well-being. Considerations of well-being also affect the treatment of incurable diseases, like Parkinson's disease. In such cases, therapies aim to minimize negative effects, helping patients lead productive and fulfilling lives despite their illness. However, well-being is not the only consideration governing medical interventions, and the commitment to patient autonomy is another core principle. This can lead to conflicts when patients act against their self-interest and reject treatments that would improve their well-being.

It has been shown that the tetradentate binding configuration of copper(I) in mbOB3b necessitates the ligation of a water molecule to the copper ion as a ligand. This has been used to argue that water is the source of electrons for reducing the bound metal ion. Others have suggested that the disulfide bridge in methanobactin's structure is the source of the electron, though XPS has shown that this bond is still intact in copper-bound methanobactin. The source of this reducing electron remains elusive at the moment.

Sources: en.wikipedia.org

Notes from published material

The diagnosis of polyneuropathy begins with a history (anamnesis) and physical examination to ascertain the pattern of the disease process (such as arms, legs, distal, proximal), if they fluctuate, and what deficits and pain are involved. If pain is a factor, determining where and how long it has been present is important; one also needs to know what disorders are present within the family and what diseases the person may have. Although diseases often are suggested by the physical examination and history alone, tests that may be employed include electrodiagnostic testing, serum protein electrophoresis, nerve conduction studies, urinalysis, serum creatine kinase (CK) and antibody testing; nerve biopsy is done sometimes. Other tests may be used, especially tests for specific disorders associated with polyneuropathies; quality measures have been developed to diagnose patients with distal symmetrical polyneuropathy (DSP).

Catch connective tissue (also called mutable collagenous tissue) is a kind of connective tissue found in echinoderms (such as starfish and sea cucumbers) which can change its mechanical properties in a few seconds or minutes through nervous control rather than by muscular means. Connective tissue, including dermis, tendons and ligaments, is one of four main animal tissues. Usual connective tissue does not change its stiffness except in the slow process of aging. Catch connective tissue, however, shows rapid, large and reversible stiffness changes in response to stimulation under nervous control. This connective tissue is specific to echinoderms in which it works in posture maintenance and mechanical defense with low energy expenditure, and in body fission and autotomy. The stiffness changes of this tissue are due to the changes in the stiffness of extracellular materials. The small amount of muscle cells that are sometimes found scattered in this tissue has little influence on the stiffness-change mechanisms.

==== Meals ==== Some bodybuilders often split their food intake into 5 to 7 meals of equal nutritional content and eat at regular intervals (e.g., every 2 to 3 hours). This approach serves two purposes: to limit overindulging in the cutting phase, and to allow for the consumption of large volumes of food during the bulking phase. Eating more frequently does not increase basal metabolic rate when compared to 3 meals a day. While food does have a metabolic cost to digest, absorb, and store, called the thermic effect of food, it depends on the quantity and type of food, not how the food is spread across the meals of the day. Well-controlled studies using whole-body calorimetry and doubly labeled water have demonstrated that there is no metabolic advantage to eating more frequently.

Shortly after the 7 October attacks and Israel's retaliation in October 2023, preventable diseases were expected to rise due to disruption in vaccination abilities. Childhood vaccinations had already dropped due to the COVID-19 pandemic, and experts cautioned about the spread of infectious diseases such as COVID-19 and measles that could be contained primarily with vaccinations. In mid-December 2023, the Gaza Health Ministry stated it had run out of vaccinations for children, which would have catastrophic repercussions. An UNOCHA representative stated the organization was having difficulty delivering childhood vaccines. On 1 January 2024 it was reported by the Palestinian Health Ministry that Israel had allowed and would facilitate the transport of vaccines into Gaza through the Rafa crossing. It was cautioned that the disbursement of the vaccines would be difficult due to displacement and destruction of infrastructure. On 29 January 2024, UNICEF reported that 16,000 children were at risk of missing routine vaccinations. In July 2024, a polio outbreak occurred in Gaza, marking the first appearance of the virus there in 25 years, and it remains ongoing. In order to contain the polio virus outbreak and limit further transmission, the WHO held two vaccination drives, one in September 2024 that reached 90% of children under 10, and one in February 2025.

== Early and personal life == Epstein was born in the Bronx, New York, and is Jewish. His parents were Jack (a salesman, born in Toronto, Ontario, Canada) and Evelyn (born in New York City). When he was three years old, his family moved to Hartsdale, New York, and then when he was 13 to the Fairfax District in Los Angeles, California. Epstein said of his father, who refused when Epstein was still a minor to sign a contract on his behalf with the Dodgers: "He wanted me to be a lawyer, rather than a bum."

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine a selective androgen receptor modulator?

No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.

Why did clinical development stop?

Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.

Is cardarine approved for medical use?

No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.

How does cardarine work in the body?

It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.

Network